Objective: To estimate annual per-patient health services utilization and costs of retinitis pigmentosa (RP) in the United States.
Methods: A retrospective claims analysis of patients with RP (N = 2990) and a 1:1 exactly matched cohort of non-RP patients was conducted using the MarketScan Commercial and Medicare Supplemental Databases. Individuals were continuously enrolled in a commercial health plan or employer-sponsored health insurance for at least 1 year.